On November 3, 2016 Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) reported an oral and a poster presentation at the 58th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting to be held December 3-6 in San Diego, California (Press release, Sunesis, NOV 3, 2016, View Source;p=RssLanding&cat=news&id=2219247 [SID1234516325]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The details for the oral presentation are as follows:
Date and Time: Monday, December 5, 2016 at 3:15 p.m. Pacific Time
Abstract Title: Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial
Session Number: 616
Session Name: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Clinical trials of Novel Drugs and Combinations in AML
Publication Number: 903
Location: Marriott Marquis San Diego Marina, San Diego Ballroom AB
The full abstract can be viewed here.
The details for the poster presentations are as follows:
Date and Time: Saturday, December 3, 2016, 5:30 PM-7:30 PM
Abstract Title: First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects
Session Number: 642
Session Name: CLL: Therapy, excluding Transplantation: Poster I
Publication Number: 2032
Location: San Diego Convention Center, Hall GH